Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.09 18.75% 0.33
CYCN closed up 18.75 percent on Wednesday, November 20, 2024, on 51 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 18.75%
Wide Bands Range Expansion 18.75%
Oversold Stochastic Weakness 18.75%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Up 5% about 21 hours ago
Up 3% about 21 hours ago
Up 2% about 21 hours ago
Up 1% about 21 hours ago
Up 10% about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclerion Therapeutics, Inc. Description

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Sickle Cell Disease Lung Diseases Orphan Disease

Is CYCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.25
52 Week Low 1.71
Average Volume 273,227
200-Day Moving Average 2.87
50-Day Moving Average 2.62
20-Day Moving Average 2.54
10-Day Moving Average 2.16
Average True Range 0.47
RSI (14) 44.13
ADX 21.06
+DI 25.86
-DI 21.32
Chandelier Exit (Long, 3 ATRs) 2.73
Chandelier Exit (Short, 3 ATRs) 3.11
Upper Bollinger Bands 3.45
Lower Bollinger Band 1.63
Percent B (%b) 0.26
BandWidth 71.79
MACD Line -0.20
MACD Signal Line -0.14
MACD Histogram -0.0634
Fundamentals Value
Market Cap 5.11 Million
Num Shares 2.45 Million
EPS -18.53
Price-to-Earnings (P/E) Ratio -0.11
Price-to-Sales 7.25
Price-to-Book 0.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.83
Resistance 3 (R3) 2.80 2.54 2.70
Resistance 2 (R2) 2.54 2.35 2.55 2.66
Resistance 1 (R1) 2.31 2.23 2.43 2.34 2.62
Pivot Point 2.05 2.05 2.10 2.06 2.05
Support 1 (S1) 1.82 1.86 1.94 1.85 1.56
Support 2 (S2) 1.56 1.74 1.57 1.52
Support 3 (S3) 1.33 1.56 1.48
Support 4 (S4) 1.36